Finerenone in Type 1 Diabetes and Chronic Kidney Disease

New England Journal of Medicine 2026 Open access

Read full text
Authors: Hiddo J.L. Heerspink, Andreas L. Birkenfeld, David Z.I. Cherney, Helen M Colhoun, Per-Henrik Groop, Linong Ji, Niels Jongs, Chantal Mathieu, Richard E. Pratley, Sylvia E. Rosas, Peter Rossing, Jay S. Skyler
+7 more Katherine R. Tuttle, Robert Lawatscheck, Meike Brinker, Markus F. Scheerer, Julie Russell, Patrick Schloemer, Janet B. McGill
DOI: 10.1056/nejmoa2512854
Cited by: 36
References: 22

Abstract

BackgroundThe nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD). The efficacy and safety of finerenone in persons with type 1 diabetes and CKD are unknown. MethodsWe conducted a phase 3 trial involving adults who had type 1 diabetes, CKD (estimated glomerular filtration rate [eGFR], 25 to

Fields of Study & Subjects

Hormonal Regulation and Hypertension Diabetes and associated disorders Adrenal Hormones and Disorders

Publication details

Journal / source
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Volume
394
Issue
10
Pages
947–957
Publication date
4 March 2026
Language
EN